Genetics & Genomics
CellCyte Genetics Signs Collaborative Agreement With Northwestern University's Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCyte's CCG-TH30 Product Candidate
Published in Cardiovascular Device Liability Week, June 15th, 2008
CellCyte Genetics Corporation (CellCyte) (BULLETIN BOARD: CCYG) has entered into a collaborative research agreement with Northwestern University's Feinberg School of Medicine to perform an acute myocardial infarction (AMI) disease model study in mice using CellCyte's CCG-TH30 product candidate. The goal of the study is to evaluate the functional benefit of the CCG-TH30 therapy in a disease model outcome study representative of the AMI (heart attack) indication. Douglas W. Losordo, M.D., a leader in cardiovascular cell therapy research and Director of Feinberg Cardiovascular Research Institute, will serve as the principal investigator on the study.
"We are extremely...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Device Liability Week
More Articles from Cardiovascular Device Liability Week
- Blue Shield of California Foundation
Blue Shield of California Foundation Awards $12.3 Million: Community Clinics and Domestic Violence Shelters Top List of Recipients - Patents
Texas Jury Awards $250 Million Patent Infringement Verdict Against Boston Scientific in Balloon Catheter Lawsuit - Abdominal Aortic Aneurysm
Findings from University of Cambridge in abdominal aortic aneurysm reported - Abdominal Aortic Aneurysm
New findings reported from D. Paolini and co-authors describe advances in abdominal aortic aneurysm - Abdominal Aortic Aneurysm
Reports from Aragon Institute of Engineering Research highlight recent research in abdominal aortic aneurysm - Abdominal Aortic Aneurysm
Scientists at Baptist Cardiac and Vascular Institute target abdominal aortic aneurysm - More from this issue of Cardiovascular Device Liability Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
